Stem Cell Therapeutics Corp. Announces Filing of Final Short Form Base Shelf Prospectus

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SSS" or "Stem Cell
Therapeutics") is pleased to announce that it filed today a final short form
base shelf prospectus (the "Prospectus") with the securities commissions in each
of the provinces of British Columbia, Alberta, Manitoba, Ontario and Nova
Scotia. The Prospectus allows Stem Cell Therapeutics to make offerings of common
shares, warrants, or units for initial aggregate proceeds of up to $15 million
during the next 25 months to potential purchasers in said provinces.


The Prospectus is expected to provide Stem Cell Therapeutics with a flexible and
efficient approach for completing future financings for research initiatives and
development.


A copy of the final short form base shelf prospectus may be obtained from the
SEDAR website at www.sedar.com or from Stem Cell Therapeutics upon request by
email at [e-mail], by mail at Suite 500, 255 5th Ave. SW,
Calgary, AB T2P 3G6 or by telephone at 403.245.5495 ext. 221.


This news release shall not constitute an offer to sell nor the solicitation of
an offer to buy nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available. 


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.